(PTH) Invesco DWA Healthcare - Ratings and Ratios

Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US46137V8524

PTH: Healthcare, Stocks, Momentum, ETF, Companies

The Invesco DWA Healthcare Momentum ETF (PTH) is an exchange-traded fund that tracks a momentum-based index of healthcare stocks, investing at least 90% of its assets in the underlying securities. This index is designed to capture the performance of at least 30 healthcare companies exhibiting strong relative strength, a key characteristic of momentum investing.

By focusing on the healthcare sector, PTH provides investors with targeted exposure to a specific industry that is often driven by innovation, regulatory changes, and demographic trends. The funds underlying index is constructed to identify companies with powerful momentum characteristics, which can be an effective strategy in trending markets.

Analyzing the funds technical profile, we observe that its current price is below its short-term and medium-term moving averages (SMA20 and SMA50), indicating a potential short-term downtrend. However, the Average True Range (ATR) suggests moderate volatility, which may present trading opportunities. Considering the 52-week high and low, the fund has experienced significant price movements, reflecting the inherent volatility of the healthcare sector.

From a fundamental perspective, PTHs Assets Under Management (AUM) stand at $100.56 million, indicating a relatively modest size compared to other ETFs in the healthcare category. While this may impact liquidity, it also suggests potential for growth as investors seek targeted exposure to the healthcare sector.

Forecasting PTHs performance, we can anticipate that its momentum-driven strategy may benefit from a resurgence in the healthcare sector, driven by innovation and demographic trends. However, the current downtrend and moderate volatility suggest caution. If the funds price were to break above its SMA20 and SMA50, it could be a bullish signal, potentially driving the price towards its 52-week high. Conversely, a decline below the 52-week low could indicate further downside. Therefore, a prudent approach would be to monitor the funds price action and adjust investment decisions accordingly.

Additional Sources for PTH ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

PTH ETF Overview

Market Cap in USD 105m
Category Health
TER 0.60%
IPO / Inception 2006-10-12

PTH ETF Ratings

Growth Rating -30.3
Fundamental -
Dividend Rating 4.96
Rel. Strength -17.3
Analysts -
Fair Price Momentum 33.00 USD
Fair Price DCF -

PTH Dividends

Dividend Yield 12m 0.06%
Yield on Cost 5y 0.07%
Annual Growth 5y %
Payout Consistency 14.8%
Payout Ratio %

PTH Growth Ratios

Growth Correlation 3m -33.1%
Growth Correlation 12m -75.2%
Growth Correlation 5y -52.1%
CAGR 5y 0.46%
CAGR/Max DD 5y 0.01
Sharpe Ratio 12m 0.92
Alpha -23.50
Beta 1.043
Volatility 22.63%
Current Volume 10.1k
Average Volume 20d 6.5k
What is the price of PTH shares?
As of June 17, 2025, the stock is trading at USD 38.47 with a total of 10,079 shares traded.
Over the past week, the price has changed by -0.90%, over one month by +5.34%, over three months by -4.37% and over the past year by -9.56%.
Is Invesco DWA Healthcare a good stock to buy?
Probably not. Based on ValueRay´s Analyses, Invesco DWA Healthcare (NASDAQ:PTH) is currently (June 2025) not a good stock to buy. It has a ValueRay Growth Rating of -30.25 and therefor a somwhat technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PTH is around 33.00 USD . This means that PTH is currently overvalued and has a potential downside of -14.22%.
Is PTH a buy, sell or hold?
Invesco DWA Healthcare has no consensus analysts rating.
What are the forecasts for PTH share price target?
According to our own proprietary Forecast Model, PTH Invesco DWA Healthcare will be worth about 37.8 in June 2026. The stock is currently trading at 38.47. This means that the stock has a potential downside of -1.64%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 37.8 -1.6%